Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314484 | 0.87 | CACNA1I (0.40) | KCNH2CACNA1IHRH3GNAO1 | |
| SCHEMBL4286396 | 0.87 | KCNH2 (0.48) | KCNH2CACNA1IHRH3GNAO1DRD2 | |
| SCHEMBL13622459 | 0.85 | HRH3 (0.40) | KCNH2CACNA1IHRH3GNAO1SMN1; SMN2 | |
| SCHEMBL18016436 | 0.84 | NCF1 (0.45) | KCNH2CACNA1IHRH3GNAO1ALDH1A1 | |
| SCHEMBL19958949 | 0.83 | KCNH2 (0.45) | KCNH2CACNA1IHRH3GNAO1 | |
| SCHEMBL824023 | 0.82 | CARM1 (0.47) | KCNH2CACNA1IHRH3SIGMAR1 | |
| SCHEMBL18872031 | 0.82 | KCNH2 (0.43) | KCNH2CACNA1IHRH3GNAO1SIGMAR1 | |
| SCHEMBL19958952 | 0.81 | KCNH2 (0.52) | KCNH2CACNA1IGNAO1SIGMAR1TMEM97 | |
| SCHEMBL19958980 | 0.81 | SLC6A1 (0.36) | KCNH2CACNA1IHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL19958983 | 0.81 | SLC6A1 (0.36) | KCNH2CACNA1IHRH3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | KCNH2 4861/4885CACNA1I 4715/4885HRH3 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.